Phase II Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced Neutropenia This study is to examine which dose of DA-3031(PEG-G-CSF) has similar efficacy and safety compared to daily G-CSF in chemotherapy-induced neutropenia.

• Country Korea, Republic of
• organs None
• Specialty None

Phase III Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced Neutropenia This study is to determine whether once-per-cycle DA-3031(PEG-G-CSF) is not inferior to daily G-CSF in chemotherapy-induced neutropenia.

• Country None
• organs None
• Specialty None